NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Jupiter Neurosciences, Inc. (JUNS) Stock Analysis

Jupiter Neurosciences, Inc. (JUNS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

JUNS

$2.78

−$0.02 (−0.71%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JUNS with… →

JUNS Key Statistics

As of Oct 21, 2026
Trading
Open
$2.75
Previous Close
$2.80
Day's Range
2.63–2.80
52-Week Range
2.25–135.75
Volume
28.57K
Valuation
Market Cap
$3.67M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
46.33
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
56.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−18.94
Financials (FY)
Revenue (FY)
$21.80K
Net Income (FY)
−$8.64M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.32M
1-Year Return
−97.71%
Dividend and dates
Avg Volume
911.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, JUNS closed at $2.78, −97.71% over 1 year.

Jupiter Neurosciences, Inc. (JUNS) has a market capitalization of $3.67M.

In fiscal 2025, JUNS reported revenue of $21.80K.

JUNS Stock Return by Calendar Year

Jupiter Neurosciences, Inc. (JUNS) return since Dec 2024: what $10,000 became

1 year
$10,000 $229
−97.71%
Since Dec 2024
$10,000 $68
−99.32%

If you had invested $10,000 in Jupiter Neurosciences, Inc. (JUNS) at the close on December 3, 2024, the earliest close on record here, it would have been worth $68 at the close on October 21, 2026: −99.32% in total, −92.99% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−96.37%
2025−90.47%
2024 (partial year)+94.90%

As of October 21, 2026.

JUNS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$21.80K−$8.64M−39,662.8%
2024$0.00−$2.44M—
2023$0.00−$4.78M—
2022$233.28K−$4.96M−2,125.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$21.80K$17.57K−$8.91M−$8.64M−39,662.8%
2024$0.00—−$3.09M−$2.44M—
2023$0.00—−$3.87M−$4.78M—
2022$233.28K—−$3.43M−$4.96M−2,125.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JUNS Valuation vs Biotechnology Median

Median of 608 stocks
MetricJUNSBiotechnology medianvs median
P/S ratio56.6613.304.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Jupiter Neurosciences, Inc. (JUNS) at $3.67M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 5 employees.

JUNS last closed at $2.78 on October 21, 2026. That is −$0.02 (−0.71%) against the previous close. The 52-week range on file runs from $2.25 to $135.75. The latest close sits 23.5% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $21.80K. The same year closed with a net loss of $8.64M. Trailing earnings per share are −18.94.

Across the 4 fiscal years on file, revenue moves from $233.28K in 2022 to $21.80K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 46.33. The price-to-sales ratio is 56.66. On price-to-sales that is 4.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Daily returns over the trailing 1 year annualize to a volatility of 120.54%. The trailing one-year total return is −97.71%. The stored price history starts on December 3, 2024, and the total return since then is −99.32%.

Growth & Income

No dividend is on file for JUNS.

The record holds one complete calendar year, 2025, which returned −90.47%. So far in 2026 the total return is −96.37%.

Peer Comparison

Jupiter Neurosciences, Inc. (JUNS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jupiter Neurosciences, Inc. JUNS $3.67M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Jupiter Neurosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Visit website →